

Clinical trials of n-3 PUFA

TrialResults-center www.trialresultscenter.org

1 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
n-3 PUFA vs placebo			
P-OM3 (Kowey) , 2010 n=663 follow-up:	omega-3 PUFA capsules at 8 g/day for the first seven days followed by 4 g/day for total of 24 weeks versus placebo	outpatients with documented symptomatic paroxysmal or persistent AF without significant structural heart disease and initially in sinus rhythm	Parallel groups double-blind

More details and results :

- rythm control for atrial fibrillation in all type of patients at <http://www.trialresultscenter.org/go-Q112>
- antiarrythmic drugs for atrial fibrillation in maintaining sinus rhythm after cardioversion at <http://www.trialresultscenter.org/go-Q113>

References

P-OM3 (Kowey), 2010:

Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation: A Randomized Controlled Trial. JAMA 2010 Nov 15; [21078810] [10.1001/jama.2010.1735](https://doi.org/10.1001/jama.2010.1735)